ArticleFrontiers in oncology2021
Fecal
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A systemic review of the role of enterotoxic Bacteroides fragilis in colorectal cancer.Neoplasia (New York, N.Y.) · 2022Pooled it
- A joint mixture Tobit method with latent microbial abundance improves detection of microbiome-disease associations in zero-inflated data.PLoS computational biology · 2026Article
- Clinical applications of gut microbiome for non-invasive diagnosis of colorectal neoplasia.Journal of gastroenterology · 2026Article
- A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening.Journal of gastrointestinal oncology · 2026Review
- The specific hallmarks, emerging roles, key mechanisms, and clinical applications of intra-tumoral microbiota in human cancers.Genes & diseases · 2026Review
- Oral microbiome contribution in colorectal carcinogenesis: polymicrobial interactions and virulence determinants.Frontiers in cellular and infection microbiology · 2026Review
- Virulome over taxonomy: refining the driver-passenger model in colorectal carcinogenesis.Frontiers in cellular and infection microbiology · 2026Review
- Metagenomic and metabolomic profiling of laterally spreading tumors identifies a microbiome with putative pro-tumorigenic features in high-grade intraepithelial neoplasia.Frontiers in microbiology · 2026Article
- Altered oral microbiome composition in mental disorders: a systematic review and meta-analysis.Journal of oral microbiology · 2025Review
- Innovative approaches in colorectal cancer screening: advances in detection methods and the role of artificial intelligence.Therapeutic advances in gastroenterology · 2025Review
- Anaerobic gut bacteria and their potential role in the initiation, exacerbation, and development of human colorectal cancer: a narrative review.Frontiers in cellular and infection microbiology · 2025Review
- The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy.Frontiers in pharmacology · 2025Review
- The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis.Molecular oncology · 2024Article
- Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma.Molecular oncology · 2024Article
- Severe pneumonia with empyema caused byThe Journal of international medical research · 2023Article
- Evaluation of enterotoxigenic Bacteroides fragilis correlation with the expression of cellular signaling pathway genes in Iranian patients with colorectal cancer.Infectious agents and cancer · 2023Article
- Tissue vs. Fecal-Derived Bacterial Dysbiosis in Precancerous Colorectal Lesions: A Systematic Review.Cancers · 2023Review
- Parvimonas micra activates the Ras/ERK/c-Fos pathway by upregulating miR-218-5p to promote colorectal cancer progression.Journal of experimental & clinical cancer research : CR · 2023Article
- Screening and epitope characterization of diagnostic nanobody against total and activatedFrontiers in immunology · 2023Article
- Microbiome analysis reveals universal diagnostic biomarkers for colorectal cancer across populations and technologies.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUp to now, non-invasive diagnosis of laterally spreading tumor (LST) and prediction of adenoma recurrence after endoscopic resection of LSTs is inevitable. This study aimed to identify a microbial signature with clinical significance of diagnosing LSTs and predicting adenoma recurrence after LSTs colectomy.
methodsWe performed 16S rRNA sequencing in 24 mucosal samples, including 5 healthy controls (HC), 8 colorectal adenoma (CRA) patients, and 11 LST patients. The differentiating microbiota in fecal samples was quantified by qPCR in 475 cases with 113 HC, 208 CRA patients, 109 LST patients, and 45 colorectal cancer (CRC) patients. We identified differentially abundant taxa among cases and controls using linear discriminant analysis effect size analysis. ROC curve was used to evaluate diagnostic values of the bacterial candidates. Pairwise comparison of AUCs was performed by using the Delong's test. The Mantel-Haenszel hazard models were performed to determine the effects of microbial compositions on recurrence free survival.
resultsThe microbial dysbiosis of LST was characterized by relative high abundance of the genus Lactobacillus-Streptococcus and the species enterotoxigenic Bacteroides fragilis (ETBF)-Peptostreptococcus stomatis (P. stomatis)-Parvimonas micra (P. micra). The abundance of ETBF, P. stomatis, and P. micra were steadily increasing in LST and CRC groups. P. stomatis behaved stronger value on diagnosing LST than the other two bacteria (AUC 0.887, 95% CI 0.842-0.931). The combination of P. stomatis, P. micra, and ETBF (AUC 0.922, 95% CI 0.887-0.958) revealed strongest diagnostic power with 88.7% sensitivity and 81.4% specificity. ETBF, P. stomatis, and P. micra were associated with malignant LST (P
conclusionsFecal microbiome signature (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.